Last updated on February 2019

Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

Brief description of study

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.


Clinical Study Identifier: TX218035

Find a site near you

Start Over

Neurotrials Research, Inc.

110 Johnson Ferry Road NE Atlanta, GA United States
  Connect »